DONATE TODAY
To Increase Patient Access

Accelerating Clinical Trial Enrollment

20x Faster Enrollment  |  80% Lower Costs

The Vision

"We are health activists leaving a legacy of social change to advance health equity for all people, regardless of income, race, gender, and location."
At Icarus Digital Therapeutics (DTx), our NextGen clinical trials optimization platform meets your needs.
Icarus Therapeutics is a TechBio company in clinical trials automation software located in California, Ukraine, and South Asia committed to public health. They are Johns Hopkins-trained epidemiologists and UC Berkeley-trained software engineers with several decades of experience from the top life science and tech sectors rebuilding and reimagining clinical trials enrollment. We are democratizing access to clinical trials enrollment and recruitment.
NextGen Optimization Platform
Patient and sponsor empowered platform accelerating clinical trial enrollment.

Patient-Centric Approach
Underrepresented patient populations represent only 2-16% of clinical trials in the U.S.​
Commitment to Partnerships
ICARUS can increase patient awareness and will enhance the patient enrollment experience through building strategic partnerships.


Icarius also provides consulting services in the fields of clinical trials optimization, clinical research, and data management on behalf of biotech and pharmaceutical companies undertaking drug trials and applications for drug approval.
Icarius Therapeutics
Following the COVID-19 pandemic, clinical trial enrollment now stands at a crossroads. Clinical research sites have finite resources. Typically, patients google their condition, search social media for a trial, see their physician for a site and/or physician investigator referral, connect with a relevant patient advocacy organization, or rummage through clinicaltrials.gov. At Icarus, we streamline clinical trial enrollment directly to patients and match with a sponsor instantly, thus removing the traditional, antiquated bottlenecks by effectively matching patients with the right trial at the right time, and with the right sponsor, thus saving both time and money. No more closing trials due to sluggish patient enrollment. No more soaring drop out rates. No more lack of patient awareness and thus lack of patient involvement. No more lack of diverse patient populations in the study. We are taking on the “elephant in the room” head on when it comes to clinical trials.
For the sponsor, finding eligible patients for clinical trials is often a slow, cumbersome, costly, and arduous process. Despite these significant investments in time and money, 90% of drug candidates in clinical trials fail. Whether because they don’t adequately treat the condition they’re meant to target or the side effects are too strong, many drug candidates never advance to the approval stage.
Icarius Therapeutics
JLABS San Diego, 3210 Merryfield Row, San Diego, CA 92121  |  1147 Walnut Street, Berkeley, CA 94707  |  617-852-7092  |  info@icarustx.ai
Contact For The Patient
https://icarustherapeutics.com/#
Contact For The Sponsor
https://icarustherapeutics.com/#

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram